---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000026"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:02:45.159871+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q1 rev $220M (+48% YoY), DMD $170M; FY23 guidance reaffirmed

## Summary
- Total revenue $220.4M vs $148.7M YoY (+48%); net product revenue $187.6M vs $129.8M.
- Translarna net revenue $115.1M (+45% YoY); Emflaza $54.6M (+12% YoY); Evrysdi royalty $30.8M (+63%).
- GAAP net loss $139.0M vs $126.7M; cash $286.3M at quarter-end vs $410.7M at Dec 31.
- Reaffirmed FY2023 total revenue guidance $940M-$1.0B; DMD franchise $545-565M.
- Four clinical readouts expected in Q2 2023, incl. registration trials for sepiapterin (PKU), vatiquinone (FA & mito disease), and PTC518 (HD) interim data.

## SEC filing metadata
- accession: 0001070081-23-000026
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000026/0001070081-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000026/tmb-20230427x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000026
- JSON: https://secwatch.observer/filing/0001070081-23-000026.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000026.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2023 results: revenue $220.4 million. Guidance reaffirmed.
  - Period: the first quarter ending March 31, 2023
  - Revenue: $220.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: this Item 2.02. ​ --- EX-99.1 (EX-99.1) --- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results – First-quarter 2023 total revenue of $220 million, representing 48% year-over-year growth - ​ – Readouts from four clinical studies expected in second quarter of 2023, three of which are registration-directed – ​ SOUTH
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000026/0001070081-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.